170 related articles for article (PubMed ID: 35486993)
1. Identification of novel and potent PROTACs targeting FAK for non-small cell lung cancer: Design, synthesis, and biological study.
Sun Y; Wang R; Sun Y; Wang L; Xue Y; Wang J; Wu T; Yin W; Qin Q; Sun Y; Zhao D; Cheng M
Eur J Med Chem; 2022 Jul; 237():114373. PubMed ID: 35486993
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, and biological evaluation of potent FAK-degrading PROTACs.
Qin Q; Wang R; Fu Q; Zhang G; Wu T; Liu N; Lv R; Yin W; Sun Y; Sun Y; Zhao D; Cheng M
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2241-2255. PubMed ID: 35978496
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis, and Evaluation of Highly Potent FAK-Targeting PROTACs.
Gao H; Wu Y; Sun Y; Yang Y; Zhou G; Rao Y
ACS Med Chem Lett; 2020 Oct; 11(10):1855-1862. PubMed ID: 33062164
[TBL] [Abstract][Full Text] [Related]
4. Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders.
Yang M; Xiang H; Luo G
Biochem Pharmacol; 2024 Jun; 224():116246. PubMed ID: 38685282
[TBL] [Abstract][Full Text] [Related]
5. Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation.
Cromm PM; Samarasinghe KTG; Hines J; Crews CM
J Am Chem Soc; 2018 Dec; 140(49):17019-17026. PubMed ID: 30444612
[TBL] [Abstract][Full Text] [Related]
6. Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity.
Koide E; Mohardt ML; Doctor ZM; Yang A; Hao M; Donovan KA; Kuismi CC; Nelson AJ; Abell K; Aguiar M; Che J; Stokes MP; Zhang T; Aguirre AJ; Fischer ES; Gray NS; Jiang B; Nabet B
Chembiochem; 2023 Oct; 24(19):e202300141. PubMed ID: 37088717
[TBL] [Abstract][Full Text] [Related]
7. FAK-targeting PROTAC demonstrates enhanced antitumor activity against KRAS mutant non-small cell lung cancer.
Liu J; Xue L; Xu X; Luo J; Zhang S
Exp Cell Res; 2021 Nov; 408(2):112868. PubMed ID: 34648846
[TBL] [Abstract][Full Text] [Related]
8. Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy.
Pang XJ; Liu XJ; Liu Y; Liu WB; Li YR; Yu GX; Tian XY; Zhang YB; Song J; Jin CY; Zhang SY
Molecules; 2021 Jul; 26(14):. PubMed ID: 34299525
[TBL] [Abstract][Full Text] [Related]
9. Discovery and Characterisation of Highly Cooperative FAK-Degrading PROTACs.
Law RP; Nunes J; Chung CW; Bantscheff M; Buda K; Dai H; Evans JP; Flinders A; Klimaszewska D; Lewis AJ; Muelbaier M; Scott-Stevens P; Stacey P; Tame CJ; Watt GF; Zinn N; Queisser MA; Harling JD; Benowitz AB
Angew Chem Int Ed Engl; 2021 Oct; 60(43):23327-23334. PubMed ID: 34416073
[TBL] [Abstract][Full Text] [Related]
10. Discovery of 7H-pyrrolo[2,3-d]pyridine derivatives as potent FAK inhibitors: Design, synthesis, biological evaluation and molecular docking study.
Wang R; Zhao X; Yu S; Chen Y; Cui H; Wu T; Hao C; Zhao D; Cheng M
Bioorg Chem; 2020 Sep; 102():104092. PubMed ID: 32707280
[TBL] [Abstract][Full Text] [Related]
11. Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK).
Zhang C; Han XR; Yang X; Jiang B; Liu J; Xiong Y; Jin J
Eur J Med Chem; 2018 May; 151():304-314. PubMed ID: 29627725
[TBL] [Abstract][Full Text] [Related]
12. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
Lu Y; Sun H
J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer.
Wang P; Zhu H; Liu J; Xie S; Xu S; Chen Y; Xu J; Zhao Y; Zhu Z; Xu J
Bioorg Chem; 2023 Feb; 131():106327. PubMed ID: 36549254
[TBL] [Abstract][Full Text] [Related]
14. FAK inhibitors in Cancer, a patent review.
Lv PC; Jiang AQ; Zhang WM; Zhu HL
Expert Opin Ther Pat; 2018 Feb; 28(2):139-145. PubMed ID: 29210300
[TBL] [Abstract][Full Text] [Related]
15. Effective degradation of EGFR
Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents.
Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M
Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660
[TBL] [Abstract][Full Text] [Related]
17. FAK PROTAC Inhibits Ovarian Tumor Growth and Metastasis by Disrupting Kinase Dependent and Independent Pathways.
Huo X; Zhang W; Zhao G; Chen Z; Dong P; Watari H; Narayanan R; Tillmanns TD; Pfeffer LM; Yue J
Front Oncol; 2022; 12():851065. PubMed ID: 35574330
[TBL] [Abstract][Full Text] [Related]
18. Development of the nonreceptor tyrosine kinase FER-targeting PROTACs as a potential strategy for antagonizing ovarian cancer cell motility and invasiveness.
Zhang Y; Xiong X; Sun R; Zhu X; Wang C; Jiang B; Yang X; Li D; Fan G
J Biol Chem; 2023 Jun; 299(6):104825. PubMed ID: 37196766
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of Wee1 kinase degraders.
Zhu S; Liu J; Xiao D; Wang P; Ma J; Hu X; Fu J; Zhou Y; Li J; Lu W
Eur J Med Chem; 2022 Dec; 243():114786. PubMed ID: 36170799
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel covalent inhibitors targeting focal adhesion kinase.
Chen T; Liu Y; Shi M; Tang M; Si W; Yuan X; Wen Y; Chen L
Bioorg Med Chem Lett; 2021 Dec; 54():128433. PubMed ID: 34757216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]